Biochemical Pharmacology · Nov 10, 2026
Metformin for the treatment of chronic liver disease: Mechanistic rationale, translational evidence, and repurposing opportunities
By Vargas-Pozada EE, Ramos-Tovar E, Márquez-Quiroga LV et al.
Chronic liver disease (CLD) is characterized by progressive hepatocellular injury, metabolic dysfunction, inflammation, fibrogenesis, and an increased risk of hepatocellular carcinoma (HCC). Despite advances in understanding CLD pathogenesis, effective therapies targeting multiple disease-driving pathways remain limited. Metformin, a biguanide widely used to treat type 2 diabetes, has emerged as a candidate for drug repurposing because of its pleiotropic metabolic and immunomodulatory effects. This narrative review examines the mechanistic rationale, translational evidence, and clinical implications of metformin in treating CLD. Experimental studies indicate that metformin modulates AMP-activated protein kinase-dependent and -independent pathways involved in hepatic lipid metabolism, mitochondrial bioenergetics, oxidative stress, autophagy, immunometabolic signaling, hepatic stellate cell activation, and hepatocarcinogenesis. In preclinical models, these effects have been associated with reduced steatosis, inflammatory injury, fibrogenesis, and tumor-promoting signaling. Epidemiological and clinical studies also suggest that metformin use is associated with improved survival in selected patients with cirrhosis and a lower risk of HCC in individuals with diabetes. Although mechanistic, experimental, and epidemiological evidence is encouraging, randomized clinical studies have not consistently shown histological improvement in metabolic dysfunction–associated steatohepatitis, and clinical findings remain heterogeneous across disease stages and etiologies. Limitations include the gap between mechanistic and clinical evidence, uncertainty regarding the relevance of proposed mechanisms, the context-dependent nature of metformin signaling, and the inherent limitations of observational studies. Overall, metformin is a biologically plausible therapeutic candidate for CLD, but its future clinical role will depend on integrating mechanistic insights with rigorous translational and clinical research to identify patients most likely to benefit.
doi.org/10.1016/j.bcp.2026.118601Open accessPubMed 43009104Interventions